Jaguar Health, Inc. stock is down -4.83% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November.
Jaguar Health, Inc. focuses on developing prescription medicines for people and animals with gastrointestinal distress. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera.